Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg

References

• Kado D, Browner W, Palermo L. Vertebral fractures and mortality in older women. Arch Intern Med 1999;159:1215-20
   PubMed Web of Science ®Google Scholar
• Empana JP, Dargent-Molina P, Bréart G, et al. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004;52:685-90
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIN consensus statement 2000;17:1-45
   Google Scholar
• Cummings SR, Melton J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• International Osteroporosis Foundation. Osteoporosis in the European community: action plan. International Osteoporosis Foundation 2003. Available at: http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/action_plan_03_e.pdf [Last accessed 3 September 2009]
   Google Scholar
• Melton J. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. J Am Med Assoc 1999;282:1344-52
   Google Scholar
• Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23:S81(Abstract 1288)
   Web of Science ®Google Scholar
• Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42
   PubMed Web of Science ®Google Scholar
• Greenspan S, Bone H, Ettinger M, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate of the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Pasco JA, Kotowicz MA, Henry MJ, et al. Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study. Osteoporos Int 2004;15:434-8
   PubMed Web of Science ®Google Scholar
• Seeman E. Strontium ranelate: vertebral and non-vertebral fracture risk reduction. Curr Opin Rheumatol 2006;18(Suppl. 1):S17-20
   PubMedGoogle Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
   PubMed Web of Science ®Google Scholar
• Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243-51
   PubMed Web of Science ®Google Scholar
• Cramer J, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with post-menopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
   PubMed Web of Science ®Google Scholar
• Recker R, Gallagher R, MacCosbe P. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Rebenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 2006;1:415-23
   PubMed Web of Science ®Google Scholar
• Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. JCEM 2007;92:1296-394
   PubMed Web of Science ®Google Scholar
• Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims database. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
   PubMed Web of Science ®Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-10
   PubMed Web of Science ®Google Scholar
• Russell R, Watts N, Ebetino F, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical safety. Osteoporosis Int 2008;19:733-59
   PubMed Web of Science ®Google Scholar
• Russell R, Croucher P, Rogers M. Bisphosphonates: pharmacology, mechanisms of action in clinical uses. Osteoporos Int 1999;2:S66-S80
   Google Scholar
• Silva MJ, Gibson LJ Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone 1997;21:191-9
   PubMed Web of Science ®Google Scholar
• Epstein S. Is cortical bone hip? What determines cortical bone properties? Bone 2007;41(Suppl. 1):S3-8
   Google Scholar
• Leu C, Luegmayr E, Freedman L, et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006;38:628-36
   PubMed Web of Science ®Google Scholar
• Bauss F, Wagner M, Hothorn L. Total administered dose of ibandronate determines its effect on bone mass and architecture in overestomised aged rats. J Rheum 2002;29:990-8
   PubMed Web of Science ®Google Scholar
• Monier-Faugere MC, Geng Z, Paschalis EP, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 1999;14:1768-78
   PubMed Web of Science ®Google Scholar
• Müller R, Hannan M, Smith SY, et al. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 2004;19:1787-96
   PubMed Web of Science ®Google Scholar
• Smith SY, Recker RR, Hannan M, et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003;32:45-55
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1 year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22
   PubMed Web of Science ®Google Scholar
• Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36-42
   PubMed Web of Science ®Google Scholar
• Brody BA, Dickey N, Ellenberg SS, et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?. J Bone Miner Res 2003;18:1105-9
   PubMed Web of Science ®Google Scholar
• Temple RJ Study designs in osteoporosis. J Bone Miner Res 2003;18:1129-32
   PubMed Web of Science ®Google Scholar
• Hochberg M, Greenspan S, Wasnich R. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metabol 2002;87:1586-92
   PubMed Web of Science ®Google Scholar
• Wasnich R, Miller P. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metabol 2000;85:231-46
   PubMed Web of Science ®Google Scholar
• European Medicines Agency 2005 Guideline on the Evaluation of New Medicinal Products in the Treatment of Osteoporosis. Available at: www.emea.eu.int/pdfs/human/ewp/ 055295en.pdf [last accessed 22 April 2009]
   Google Scholar
• Silverman SL, Cummings SR, Watts N. Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 2008;23:159-65
   PubMed Web of Science ®Google Scholar
• US Dept of Health and Human Services. Office of the Surgeon General. Bone health and osteoporosis: A report of the Surgeon General. October 14, 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth [Last accessed 3 September 2009]
   Google Scholar
• Miller PD Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005;3:103-10
   PubMedGoogle Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Risedronate 1998 US prescribing information. Available at: http://www.actonel.com/prescribinginformation.jsp [Last accessed 3 September 2009]
   Google Scholar
• Ste-Marie L, Brown J, Beary J, et al. Once-a-month risedronate is as effective as oral daily 5 mg risedronate in postmenopausal osteoporosis: Phase II study results. Osteoporos Int 2006;17(Suppl. 2):S210–11 [abstract]
   Google Scholar
• Bauss F, Schimmer R. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeut Clin Risk Manag 2006;2:3-18
   PubMedGoogle Scholar
• Gieschke R, Reginster J-Y. Successful prediction of biomarker response to oral monthly ibandronate. Osteoporosis Int 2004;15:S97 (Abstract P359SU)
   Web of Science ®Google Scholar
• Reginster J-Y, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metabol 2005;90:5018-24
   PubMed Web of Science ®Google Scholar
• Barrett J, Worth E, Bauss F. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
   PubMed Web of Science ®Google Scholar
• Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008;27:955-60
   PubMed Web of Science ®Google Scholar
• Miller PD, Cooper C, Neate C, et al. Long-term efficacy of monthly oral ibandronate: results from the MOBILE LTE study. Osteoporos Int 2008;19(Suppl. 2):299 (Abstract P218TH)
   Google Scholar
• Felsenberg D, Czerwinski E, Stakkestad J, et al. Efficacy of monthly oral ibandronate is maintained over 5 years: the MOBILE LTE study. Osteoporos Int 2009;20(Suppl. 1):S15 (Abstract 0C32)
   Google Scholar
• Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-7
   PubMed Web of Science ®Google Scholar
• Harris ST, Blumentals WA, Miller PD Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of Phase III studies. Curr Med Res Opin 2008;24:237-45
   PubMed Web of Science ®Google Scholar
• Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-9
   PubMed Web of Science ®Google Scholar